Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2014 Publisher: Dr Falk Pharma UK Ltd, Unit K, Bourne End Business Park, Cores End Road, Bourne End, Buckinghamshire, SL8 5AS
Ursofalk 250mg hard capsules.
Pharmaceutical Form |
---|
Capsule, hard. White, opaque, hard gelatin capsules (size 0) containing a white compressed powder or granules. |
Each capsule contains 250mg ursodeoxycholic acid (UDCA) as the active ingredient.
For a full list of excipients, see section 6.1
Active Ingredient | Description | |
---|---|---|
Ursodeoxycholic acid |
The ursodeoxycholic acid converts lithogenic bile in non-lithogenic bile and gradually dissolves the cholesterol gallstones. |
List of Excipients |
---|
Ursofalk 250mg hard capsules contain the following excipients: Maize starch, silica colloidal anhydrous, magnesium stearate, gelatin, titanium dioxide, sodium lauryl sulphate. |
Clear PVC blister strips with aluminium foil backing packed in cardboard cartons. Available in cartons containing 60 capsules packaged in six blister strips of 10 capsules or 100 capsules packaged in 4 blister strips of 25 capsules.
Dr Falk Pharma UK Ltd, Unit K, Bourne End Business Park, Cores End Road, Bourne End, Buckinghamshire, SL8 5AS
PL 10341/0006
Date of First Authorisation: 31 December 2004
Date of Last Renewal: 14 November 2009
Drug | Countries | |
---|---|---|
URSOFALK | Austria, Australia, Cyprus, Germany, Ecuador, Estonia, Hong Kong, Croatia, Ireland, Israel, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.